Rare diseases
Investigational molecules
Locations
100 Campus Drive, 07932-1020, United States
Clinical research activity is centered on Waldenstrom macroglobulinemia, with attention to patients whose disease has persisted after multiple prior therapies. The sponsor’s funded work reflects a focused interest in this rare B-cell malignancy and its treatment landscape.
The research program is directed toward outcomes relevant to advanced disease in the hematology-oncology setting.
Cellectar Biosciences Inc. runs clinical trials in conditions such as Waldenstrom's macroglobulinaemia, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
